489 related articles for article (PubMed ID: 26045121)
1. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
[TBL] [Abstract][Full Text] [Related]
2. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
4. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic significance of sunitinib-induced "off-target" side effects].
Maráz A; Cserháti A; Uhercsák G; Szilágyi E; Varga Z; Kahán Z
Magy Onkol; 2014 Sep; 58(3):167-72. PubMed ID: 25260080
[TBL] [Abstract][Full Text] [Related]
6. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
[TBL] [Abstract][Full Text] [Related]
8. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off.
Kondo T; Takagi T; Kobayashi H; Iizuka J; Nozaki T; Hashimoto Y; Ikezawa E; Yoshida K; Omae K; Tanabe K
Jpn J Clin Oncol; 2014 Mar; 44(3):270-7. PubMed ID: 24474815
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
[TBL] [Abstract][Full Text] [Related]
11. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
Li XS; Wu X; Zhao PJ; Huang LH; Song Y; Gong K; Shen C; Yu W; Song G; Zhao Z; Zhang Z; Zhang Q; Wang G; He ZS; Zhou LQ; Jin J
Chin Med J (Engl); 2011 Sep; 124(18):2920-4. PubMed ID: 22040503
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
Atkinson BJ; Kalra S; Wang X; Bathala T; Corn P; Tannir NM; Jonasch E
J Urol; 2014 Mar; 191(3):611-8. PubMed ID: 24018239
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kaymakcalan MD; Xie W; Albiges L; North SA; Kollmannsberger CK; Smoragiewicz M; Kroeger N; Wells JC; Rha SY; Lee JL; McKay RR; Fay AP; De Velasco G; Heng DY; Choueiri TK
Cancer; 2016 Feb; 122(3):411-9. PubMed ID: 26540173
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
[TBL] [Abstract][Full Text] [Related]
18. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ
Lancet Oncol; 2016 Mar; 17(3):378-388. PubMed ID: 26794930
[TBL] [Abstract][Full Text] [Related]
19. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
20. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.
Akaza H; Naito S; Ueno N; Aoki K; Houzawa H; Pitman Lowenthal S; Lee SY
Jpn J Clin Oncol; 2015 Jun; 45(6):576-83. PubMed ID: 25917359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]